Drug intelligence / Profile preview

CP101

Development stage: Phase 2
Lead developer: Finch Therapeutics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

CP101 is an investigational, orally administered, lyophilized microbiome therapeutic. It is a "Complete Consortia" product designed to deliver a diverse community of microbes derived from screened, healthy human donors to restore a healthy gut microbiome. [2, 9, 15] Originally developed at the University of Minnesota and in-licensed by Crestovo, it became the lead asset for Finch Therapeutics following a merger. While its Phase 3 trial (PRISM4) for the prevention of recurrent *Clostridioides difficile* infection was discontinued in January 2023 as part of a corporate restructuring, the asset is still being explored in other indications. [1, 4, 16] An investigator-sponsored Phase 1 trial is currently evaluating CP101 for the treatment of mild-to-moderate ulcerative colitis. [3, 5, 9]

Brand names: FSM®
Other names: Complete Consortia microbiome therapeuticFull Spectrum Microbiota

Beyond the preview

Go deeper on CP101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP101.

Explore the full profile